Chinese Journal of Dermatology ›› 2025, e20230345.doi: 10.35541/cjd.20230345

• Research Reports • Previous Articles     Next Articles

Genetic variation analysis in three cases of acute generalized exanthematous pustulosis caused by hydroxychloroquine

Shao Yi1, Zhang Shuai1, Dou Jinfa1, Bian Lu1, Fan Xing1, Li Ming2, Liu Hongwei1, Wang Jianbo1, Li Jianguo1   

  1. 1Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou 450003, China; 2Department of Dermatology, Children's Hospital of Fudan University, Shanghai 200032, China
  • Received:2023-06-15 Revised:2024-07-18 Online:2025-02-15 Published:2025-02-10
  • Contact: Wang Jianbo; Li Jianguo E-mail:wangjianbo1020@163.com; drljg006@163.com
  • Supported by:
    Henan Health Young and Middle-aged Discipline Leader Training Project

Abstract: 【Abstract】 To report 3 cases of acute generalized exanthematous pustulosis (AGEP) caused by hydroxychloroquine. All three patients were females, aged 23, 30, and 28 years respectively. In cases 1 and 3, the rashes appeared 4 days and 12 days after the treatment with hydroxychloroquine for systemic lupus erythematosus; case 2, who was 8 weeks pregnant, developed rashes 10 days after starting hydroxychloroquine treatment for antiphospholipid syndrome. All the 3 patients had high fever, and clinically presented with generalized round or oval-shaped edematous erythema on the face, neck, trunk and limbs, covered with a large number of pinhead-sized pustules, and with multiple erythema multiforme-like lesions on the trunk and both upper limbs, including targetoid lesions. Mutations in the IL36RN gene were identified in all the 3 patients: a homozygous mutation c.115+6T>C in the IL36RN gene was found in case 1, and her parents were heterozygous carriers; case 2 inherited the heterozygous mutation c.115+6T>C in the IL36RN gene from her mother; the heterozygous mutation c.115+6T>C found in case 3 was a de novo mutation. A diagnosis of AGEP was made. Cases 1 and 2 received subcutaneous injections of adalimumab in addition to the treatment of their underlying diseases, and skin lesions markedly regressed after 1 week of treatment; case 3 was treated with high-dose glucocorticoids, and lesions subsided after 4 weeks; no significant adverse reactions were observed in cases 1 and 2, however, femoral head necrosis was noted in case 3. During a follow-up period of 42 months, none of the patients experienced a recurrence, and case 2 gave birth to a healthy baby boy after 8-month treatment.

Key words: Acute Generalized Exanthematous Pustulosis, Hydroxychloroquine, IL36RN gene, Adalimumab